If you’ve been researching medical weight loss, you’ve almost certainly come across the names semaglutide and tirzepatide. These two injectable medications have transformed the weight loss landscape, giving patients results that were previously only achievable through surgery.
But with two highly effective options on the table, the natural question is: which one is better for you?
The answer isn’t one-size-fits-all. Both medications work through similar mechanisms, but they have meaningful differences in how they function, how much weight patients typically lose, what the side effects look like, and what the experience is like for the patient.
As a board-certified physician who prescribes both medications in my practice, I want to give you an honest, thorough comparison so you can have an informed conversation with your doctor about which option fits your body, your health history, and your goals.
How Semaglutide Works
Semaglutide is a GLP-1 receptor agonist. GLP-1 (glucagon-like peptide-1) is a hormone your body naturally produces in the gut after you eat. It signals your brain that you’re full, slows down how quickly food moves through your stomach, and helps regulate blood sugar levels.
Semaglutide mimics this hormone, but in a much more potent and long-lasting form. When you take semaglutide, you experience reduced appetite, fewer food cravings, a prolonged feeling of fullness after eating, and improved blood sugar regulation. Many patients also describe a significant reduction in “food chatter” — that constant mental noise about what to eat next, when to eat, and the ongoing internal negotiation around food. For many people, quieting that food noise is one of the most life-changing aspects of treatment.
You may recognize semaglutide by its brand names. Ozempic is the formulation approved for type 2 diabetes. Wegovy is the higher-dose formulation approved specifically for weight management. Both contain semaglutide — the difference is the approved indication and dosing. An oral form of semaglutide (Rybelsus) also exists and is approved for type 2 diabetes, with a higher-dose oral formulation being studied for weight loss. However, oral semaglutide generally produces less weight loss than the injectable form and may have more variable absorption, which is why the injectable version remains the preferred option for most weight management patients.
Semaglutide is administered as a once-weekly subcutaneous injection. The dose is gradually increased over several weeks to help your body adjust and minimize side effects.
How Tirzepatide Works
Tirzepatide takes a different approach. Rather than targeting just one hormone receptor, it’s a dual-acting medication that activates both the GLP-1 receptor and the GIP receptor (glucose-dependent insulinotropic polypeptide).
GIP is another naturally occurring incretin hormone that works alongside GLP-1 to regulate appetite, blood sugar, and fat metabolism. By activating both pathways simultaneously, tirzepatide provides a more comprehensive metabolic effect.
In practical terms, this dual mechanism means tirzepatide may provide stronger appetite suppression, an even greater reduction in food noise and cravings, enhanced blood sugar control, improved fat metabolism, and potentially greater weight loss in many patients.
You’ll see tirzepatide sold under the brand names Mounjaro (approved for type 2 diabetes) and Zepbound (approved for weight management).
Like semaglutide, tirzepatide is a once-weekly subcutaneous injection with a gradual dose-escalation schedule.
Semaglutide vs. Tirzepatide: Head-to-Head Comparison
Weight Loss Results
This is the question everyone wants answered, and the clinical data gives us a clear picture.
In the landmark STEP clinical trials for semaglutide, participants lost an average of approximately 15 percent of their body weight over 68 weeks. For someone who weighs 220 pounds, that translates to roughly 33 pounds.
The SURMOUNT clinical trials for tirzepatide showed even more dramatic results. At the highest doses, participants lost an average of approximately 21 percent of their body weight — and some achieved reductions of 25 percent or more. For that same 220-pound person, that’s approximately 46 pounds.
In 2025, the SURMOUNT-5 trial became the first head-to-head study directly comparing the two medications. The results published in the New England Journal of Medicine confirmed that tirzepatide produced significantly greater weight loss than semaglutide — with participants losing an average of 20.2 percent of body weight on tirzepatide compared to 13.7 percent on semaglutide over 72 weeks.
Real-world studies have generally supported these findings, though individual results vary considerably. Some patients respond exceptionally well to semaglutide, while others see better results with tirzepatide. Genetics, starting weight, metabolic health, diet, activity level, and medication adherence all play roles.
How They Feel Day to Day
Both medications reduce appetite and change your relationship with food. Most patients describe feeling satisfied with smaller portions, experiencing fewer cravings — particularly for high-sugar and high-fat foods — and finding it easier to make healthier choices without the constant battle of willpower.
One of the most powerful effects patients report is the dramatic reduction in food chatter. That relentless mental loop — thinking about your next meal while you’re still eating the current one, bargaining with yourself about snacks, feeling controlled by food — often quiets significantly within the first few weeks of treatment. For many patients, this mental freedom is even more meaningful than the number on the scale.
Some patients on tirzepatide report a more pronounced effect on appetite suppression and food noise reduction, likely due to the dual hormone action. However, this varies by individual. The “right” medication is ultimately the one that helps you eat less while still enjoying food and maintaining adequate nutrition.
Side Effects
The side effect profiles for semaglutide and tirzepatide are similar because they share the GLP-1 mechanism. The most common side effects are gastrointestinal and typically occur when starting the medication or during dose increases.
Common side effects of both medications include: nausea (the most frequently reported), diarrhea, constipation, stomach pain or discomfort, decreased appetite, and vomiting.
For most patients, these side effects are mild to moderate and improve significantly within the first few weeks as your body adjusts. The gradual dose-escalation protocol is specifically designed to minimize these effects.
Some studies suggest tirzepatide may cause slightly more nausea at higher doses due to its dual-action mechanism, though this finding is not consistent across all research.
Less common side effects that should be discussed with your doctor include: gallbladder problems, pancreatitis (rare but serious), changes in heart rate, and injection site reactions.
Both medications carry warnings about thyroid C-cell tumors based on animal studies, and they are not recommended for patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
The key to managing side effects with either medication is working with an experienced physician and a dedicated health coaching team who can adjust your dosing schedule, monitor your response, provide guidance on dietary strategies that reduce gastrointestinal discomfort, and support you through the adjustment period.
The Microdosing Approach: Why More Isn’t Always Better
One of the most important things I want patients to understand is that the maximum dose is not always the right dose.
Clinical trials test medications at specific dose levels to measure efficacy. But in clinical practice, we see patients every day who achieve excellent results at lower doses — sometimes significantly lower than the maximum studied in trials. This is where a microdosing approach becomes valuable.
Microdosing — using a lower, carefully calibrated dose — can significantly reduce side effects like nausea, vomiting, and gastrointestinal discomfort while still providing meaningful appetite suppression, food noise reduction, and steady weight loss. Some patients find that a low dose is all they need to quiet the food chatter, feel satisfied with less, and lose weight at a sustainable pace.
The benefits of a microdosing strategy include fewer and milder side effects, especially gastrointestinal symptoms. It also means lower medication cost since you’re using less product. Many patients experience more gradual, sustainable weight loss that’s easier to maintain, along with better overall tolerance that allows them to stay on medication long-term without interruptions.
Not every patient needs the highest dose to get results. A skilled physician monitors your progress, listens to how your body is responding, and finds the dose that delivers the best balance of efficacy and tolerability — not just the dose that a clinical trial protocol prescribes.
In our medical weight loss program, we tailor dosing to each patient. Some patients do beautifully on a microdose and never need to increase. Others benefit from gradually titrating up. The key is personalized medical guidance and ongoing health coaching — not a one-size-fits-all prescription.
Blood Sugar and Metabolic Benefits
Both medications were originally developed for type 2 diabetes, and they both improve blood sugar control significantly. However, tirzepatide has shown a slight edge in reducing HbA1c levels in clinical trials, with average reductions of 2 to 2.5 percent compared to 1 to 2 percent for semaglutide.
Even if you don’t have diabetes, these metabolic benefits matter. Many patients with obesity have some degree of insulin resistance, and improving insulin sensitivity can support long-term weight management, reduce inflammation, and lower your risk of developing type 2 diabetes, cardiovascular disease, and metabolic syndrome.
Cardiovascular Benefits
Semaglutide (as Wegovy) has completed a major cardiovascular outcomes trial — the SELECT trial — which demonstrated a 20 percent reduction in major cardiovascular events in patients with obesity and established cardiovascular disease. This is a significant finding that positions semaglutide as the first weight loss medication proven to also reduce heart attack and stroke risk.
Tirzepatide has cardiovascular outcome data emerging as well, with early results showing promise. If you have existing cardiovascular risk factors, this distinction is worth discussing with your physician.
Making Treatment Affordable
Cost is one of the biggest concerns patients have about GLP-1 medications, and understandably so. Brand-name versions of these medications can carry retail prices exceeding $1,000 per month, which puts them out of reach for many people.
That’s why our practice offers compounded semaglutide and tirzepatide as part of our medical weight loss program. Compounded formulations are prepared by licensed, accredited compounding pharmacies and contain the same active ingredient at a fraction of the brand-name cost. This makes treatment accessible to patients who might otherwise be unable to afford it.
When you work with our practice, medication is included as part of a comprehensive, physician-supervised weight loss program that also includes health coaching, nutritional guidance, lab monitoring, and ongoing support. You’re not just getting a prescription — you’re getting a complete medical team dedicated to your results.
Combined with a microdosing approach where appropriate, many of our patients find that treatment is significantly more affordable than they expected — because they achieve results at lower doses, which means less medication used per month.
Which Medication Should You Choose?
There is no universally “better” medication. The right choice depends on your individual circumstances, and here’s how I guide that decision in my practice.
Tirzepatide may be the stronger option if: you have a significant amount of weight to lose (BMI 35 or higher), you have type 2 diabetes or significant insulin resistance, you’ve tried semaglutide and plateaued, you want the most aggressive approach to weight reduction, or the food noise and cravings are your most dominant challenge.
Semaglutide may be the better starting point if: you have established cardiovascular disease or significant heart risk factors (given the proven SELECT trial data), you prefer a medication with a longer real-world track record, you’re sensitive to gastrointestinal side effects and want to start conservatively, or your weight loss goals are moderate (15 percent or less of body weight).
Important: Either medication should be prescribed as part of a supervised medical weight loss program — not in isolation. The best outcomes happen when medication is combined with nutritional guidance, health coaching, lifestyle modifications, and ongoing physician monitoring.
Why Medical Supervision and Health Coaching Matter
You may have seen these medications offered through online pharmacies, telehealth apps, or medspas with minimal medical oversight. While access to effective weight loss medication is a good thing, the way it’s prescribed and managed makes a significant difference in your results and safety.
In our medical weight loss program, we begin with a comprehensive evaluation — including lab work, metabolic assessment, and a full health history — before prescribing anything. Our physician and health coaching team monitor your progress regularly, adjust dosing based on your individual response, screen for side effects, ensure you’re maintaining adequate nutrition, and address any underlying metabolic issues that affect weight management.
This level of support is what separates a medical weight loss program from simply “getting a shot.” Our health coaches work alongside Dr. Reed to provide ongoing accountability, meal planning guidance, behavioral support, and troubleshooting for side effects — all of which dramatically improve outcomes and safety.
Weight loss medication works best when it’s one component of a complete program — not the entire program. The patients who achieve lasting results are the ones who use the medication as a tool to build sustainable habits, not as a standalone solution.
What Happens When You Stop the Medication?
This is one of the most important questions to consider, and the research is clear: stopping either semaglutide or tirzepatide typically results in weight regain if no other changes have been made.
Studies show that most patients regain a significant portion of lost weight within a year of discontinuing treatment. This is not a personal failure — it reflects the biological reality of how the body defends its weight set point.
That’s why we approach medical weight loss as a long-term strategy, not a quick fix. For some patients, staying on medication at a maintenance dose — often a microdose — is the right decision. For others, a period of medication-assisted weight loss followed by a structured transition to maintenance — including continued health coaching, nutritional support, hormone optimization, and metabolic monitoring — provides lasting results.
The goal is never just to lose weight. The goal is to transform your metabolic health, change your relationship with food, quiet the food chatter for good, and create a sustainable path forward — with or without ongoing medication.
Key Takeaways
Both semaglutide and tirzepatide are powerful, clinically proven tools for weight management. Tirzepatide currently shows greater average weight loss in clinical trials due to its dual-hormone mechanism, while semaglutide has the strongest cardiovascular outcomes data and a longer track record. Both medications dramatically reduce food noise and cravings, which for many patients is the most transformative benefit. Side effects are similar for both and usually manageable — especially with a microdosing approach and medical supervision. Not every patient needs the maximum dose to achieve meaningful results. Neither medication is a standalone solution — the best results come from a comprehensive medical weight loss program with physician oversight and health coaching. Our practice offers affordable compounded formulations as part of a complete weight loss program, making treatment accessible without sacrificing medical quality or safety.
The most important step isn’t choosing between these two medications. It’s choosing to take action and work with a medical team that understands obesity as a complex metabolic condition — not a character flaw — and can guide you toward the healthiest version of yourself.
Ready to find out which weight loss medication is right for you? Schedule a consultation with Dr. Myra Reed for a comprehensive evaluation, personalized dosing plan, and ongoing health coaching support. Call 850-249-5000 or book online.
Frequently Asked Questions About Semaglutide and Tirzepatide
Q: Is tirzepatide more effective than semaglutide for weight loss?
In clinical trials, tirzepatide has consistently shown greater average weight loss than semaglutide. The SURMOUNT-5 head-to-head trial found participants lost 20.2 percent of body weight on tirzepatide compared to 13.7 percent on semaglutide over 72 weeks. However, individual results vary significantly, and some patients respond better to semaglutide based on their unique physiology and health profile.
Q: What is the difference between semaglutide and tirzepatide?
Semaglutide is a GLP-1 receptor agonist, meaning it mimics one gut hormone to reduce appetite and regulate blood sugar. Tirzepatide is a dual GLP-1 and GIP receptor agonist, targeting two hormones simultaneously for a more comprehensive metabolic effect. Both are once-weekly injectable medications used for type 2 diabetes management and weight loss. Both also significantly reduce food chatter and cravings.
Q: What are the side effects of semaglutide and tirzepatide?
The most common side effects for both medications are gastrointestinal — nausea, diarrhea, constipation, stomach pain, and decreased appetite. These typically occur during the initial weeks or during dose increases and improve as your body adjusts. A microdosing approach can significantly reduce the severity and frequency of side effects. Serious side effects are rare but can include pancreatitis and gallbladder problems. Medical supervision with a physician and health coaching team is important for monitoring and managing side effects safely.
Q: How much weight can I expect to lose on these medications?
Results vary by individual, but clinical trial averages provide a useful benchmark. Semaglutide patients typically lose 12 to 15 percent of body weight. Tirzepatide patients typically lose 15 to 22 percent of body weight. Real-world results depend on dosing, duration of treatment, dietary changes, physical activity, health coaching engagement, and individual metabolic factors.
Q: What is microdosing GLP-1 medications and does it work?
Microdosing refers to using a lower, carefully calibrated dose of semaglutide or tirzepatide rather than automatically escalating to the maximum dose. Many patients achieve excellent results — including significant appetite suppression, reduced food noise, and steady weight loss — at doses well below the maximum. Microdosing also significantly reduces side effects and lowers medication cost. A skilled physician determines the optimal dose for each patient based on their individual response rather than following a one-size-fits-all protocol.
Q: How long do you have to take semaglutide or tirzepatide?
Both medications are currently intended for long-term use. Research shows that discontinuing treatment often leads to weight regain. Some patients remain on medication at a maintenance microdose indefinitely, while others may transition off under medical supervision with a structured plan that includes continued health coaching, nutritional support, and lifestyle modifications to maintain their results.
Q: Can I take semaglutide or tirzepatide if I don’t have diabetes?
Yes. Both medications have FDA-approved formulations specifically for weight management in adults with obesity (BMI of 30 or higher) or adults with a BMI of 27 or higher who have at least one weight-related health condition such as high blood pressure, high cholesterol, or obstructive sleep apnea. A medical evaluation will determine whether you are a candidate.
Q: What is food noise and do these medications help with it?
Food noise, sometimes called food chatter, is the constant mental preoccupation with food — thinking about what to eat, when to eat, negotiating with yourself about portions or snacks, and feeling controlled by cravings. Both semaglutide and tirzepatide significantly reduce food noise for most patients, often within the first few weeks of treatment. Many patients describe this as one of the most life-changing effects of the medication — the mental freedom from being consumed by thoughts about food.
Q: Do these weight loss injections work without diet and exercise?
The medications will reduce appetite and produce some weight loss on their own, but the best results — and the most sustainable ones — come from combining medication with nutritional guidance, regular physical activity, health coaching, and behavioral support. In clinical trials, all participants also received lifestyle counseling, which is part of why the results were so strong.
Q: Is there an oral version of semaglutide for weight loss?
There is an oral form of semaglutide (brand name Rybelsus) currently approved for type 2 diabetes, and a higher-dose oral formulation has been studied for weight management. However, oral semaglutide generally produces less weight loss than the injectable form and has more variable absorption depending on how it is taken. For most weight loss patients, the injectable version remains the preferred and more effective option.
Q: Is compounded semaglutide or tirzepatide safe?
Compounded versions of these medications are safe and effective when prescribed by a qualified physician and sourced from a licensed, accredited compounding pharmacy. In our practice, we use compounded semaglutide and tirzepatide as part of our comprehensive medical weight loss program, providing patients with an affordable option that includes physician oversight, health coaching, lab monitoring, and ongoing support. This ensures the same quality of care and safety as brand-name medications at a significantly lower cost.
Q: Can semaglutide or tirzepatide help with hormonal weight gain?
Yes. Both medications can be particularly effective for weight gain related to hormonal changes, including perimenopause, menopause, thyroid disorders, and insulin resistance. In our practice, we often address weight management alongside hormone optimization for the most comprehensive results. When hormonal imbalances are corrected concurrently, patients tend to see better and more sustained weight loss outcomes.
Q: What is the difference between Ozempic, Wegovy, Mounjaro, and Zepbound?
Ozempic and Wegovy both contain semaglutide. Ozempic is FDA-approved for type 2 diabetes at lower doses. Wegovy is approved for weight management at higher doses. Mounjaro and Zepbound both contain tirzepatide. Mounjaro is approved for type 2 diabetes. Zepbound is approved for weight management. The active ingredients within each pair are identical — the difference is the approved indication and dosing. An oral form of semaglutide called Rybelsus also exists but is generally less effective for weight loss than the injectable versions.